LEXINGTON, Mass.--(BUSINESS WIRE)--SynapDx Corporation and Illumina, Inc. have formed an alliance joining SynapDx’s proprietary autism technologies with Illumina’s sequencing platform to develop early detection tools for autism spectrum disorders (ASDs). The companies will also leverage their joint expertise to broadly evaluate other opportunities in neurodevelopment.
“SynapDx and Illumina share a vision of better pediatric care through the use of advanced molecular assays and sequencing technologies,” said Stanley Lapidus, SynapDx’s CEO. “We look forward to broadly collaborating on multiple joint initiatives.”
SynapDx’s breakthrough blood-based autism spectrum disorder (ASD) test, currently in clinical development, is designed to help clinicians identify children with autism earlier than they do today.
“Our relationship with SynapDx highlights our commitment to collaborating with cutting-edge companies doing truly innovative work that will improve patient care,” said Matt Posard, senior vice president and general manager of Illumina's Translational and Consumer Genomics business. “SynapDx’s commitment to the early detection of autism makes our work together truly meaningful, and we are pleased to join forces in this important effort.”
About SynapDx Corp.
SynapDx is a private company developing laboratory diagnostic services for autism and neurodevelopmental disorders, with the initial goal of enabling earlier detection of autism spectrum disorders (ASDs). The company collaborates with ASD experts at leading institutions. SynapDx was founded in 2010 and is based in Lexington, Mass. SynapDx’s investors include North Bridge Venture Partners, General Catalyst Partners and LabCorp.